Homepage
Author:
Boehringer Ingelheim Limited
Posted Date:
April 9, 2026
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
Boehringer Ingelheim Limited
April 9, 2026
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
Boehringer Ingelheim Limited
April 9, 2026
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
Boehringer Ingelheim Limited
March 25, 2026
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
Boehringer Ingelheim Limited
March 18, 2026
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
Boehringer Ingelheim Limited
January 28, 2026
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Boehringer Ingelheim Limited
January 28, 2026
Prev
1
2
